Table 2 Follow up and therapy modalities of patients with Mooren’s ulceration
Case No. | Follow up time (month) | Numbers of AM- transplantation/Surgical procedures | Immunosuppressive therapy | Topical immunosuppressivetherapy | BCVA at initial visit | BCVA at last follow up | Epithelialisation (including conjunctivalisation) |
|---|---|---|---|---|---|---|---|
1 | 112 | OD: 2x + KPL | Cyclophosphamide (i.v.; ineffective) FK-506 | Cyclosporin A AT 0.5% | OD: < 20/4000 | OD: <20/4000 | 2 month after AMT and effective immunosuppressive therapy |
OS: 3x | OS: 20/4000 | OS: 20/4000 | |||||
2 | 75 | OD: 1x | Cyclosporin A (orally) | Cyclosporin A AT 0.5% | OD: 20/2000 | OD: 20/4000 | 3 month after AMT and effective immunosuppressive therapy |
3 | 14 | OD: 4x | Cylclophosphamide (i.v.) | Cyclosporin A AT 0.5% | OD: 20/80 | OD: 20/2000 | 1 month after AMT and effective immunosuppressive therapy |
4 | 12 | OD: 1x | Cyclophosphamide (i.v.) | Cyclosporin A AT 0.5% | OD: 20/32 | OD: 20/80 | 1 month after AMT and effective immunosuppressive therapy |
5 | 144 | OD: 7x + conjunctival resection | Cyclophosphamide (i.v.; ineffective) Cyclosporin A (orally; ineffective) Tacrolimus | Cyclosporin A AT 0.5% | OD: 20/32 | OD: <20/4000 | 3 month after AMT and effective immunosuppressive therapy |
OS: 20/20 | OS: 20/32 | ||||||
6 | 232 | OD: 4x + KPL enucleation | Cyclophosphamide (i.v.) | Cyclosporin A AT 0.5% | OD: 20/25 | OD: - | 3 month after KPL and effective immunosuppressive therapy |
OS: 20/25 | OS: 20/40 | ||||||
7 | 30 | OD: 5x + conjunctival resection | Cyclophosphamide (i.v.) Azathioprine | Cyclosporin A AT 0.5% | OD: 20/320 | OD: 20/800 | 3 month after AMT and effective immunosuppressive therapy |
OS: 3x + conjunctival resection | OS: 20/32 | OS: 20/63 |